DE102020128677A1 - Ein neues Target zur Behandlung der Nierenfibrose - Google Patents

Ein neues Target zur Behandlung der Nierenfibrose Download PDF

Info

Publication number
DE102020128677A1
DE102020128677A1 DE102020128677.5A DE102020128677A DE102020128677A1 DE 102020128677 A1 DE102020128677 A1 DE 102020128677A1 DE 102020128677 A DE102020128677 A DE 102020128677A DE 102020128677 A1 DE102020128677 A1 DE 102020128677A1
Authority
DE
Germany
Prior art keywords
nkd2
cells
protein
cell
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE102020128677.5A
Other languages
German (de)
English (en)
Inventor
Rafael Johannes Thomas Kramann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rheinisch Westlische Technische Hochschuke RWTH
Original Assignee
Rheinisch Westlische Technische Hochschuke RWTH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rheinisch Westlische Technische Hochschuke RWTH filed Critical Rheinisch Westlische Technische Hochschuke RWTH
Priority to DE102020128677.5A priority Critical patent/DE102020128677A1/de
Priority to US18/249,694 priority patent/US20240391985A1/en
Priority to EP21802638.3A priority patent/EP4237078A1/de
Priority to CA3195914A priority patent/CA3195914A1/en
Priority to CN202180087798.6A priority patent/CN116783210A/zh
Priority to JP2023526269A priority patent/JP2023549706A/ja
Priority to PCT/EP2021/080068 priority patent/WO2022090434A1/de
Priority to KR1020237017649A priority patent/KR20230098243A/ko
Publication of DE102020128677A1 publication Critical patent/DE102020128677A1/de
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
DE102020128677.5A 2020-10-30 2020-10-30 Ein neues Target zur Behandlung der Nierenfibrose Pending DE102020128677A1 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE102020128677.5A DE102020128677A1 (de) 2020-10-30 2020-10-30 Ein neues Target zur Behandlung der Nierenfibrose
US18/249,694 US20240391985A1 (en) 2020-10-30 2021-10-28 Nkd2 as target for treating renal fibrosis
EP21802638.3A EP4237078A1 (de) 2020-10-30 2021-10-28 Nkd2 als target zur behandlung von nierenfibrose
CA3195914A CA3195914A1 (en) 2020-10-30 2021-10-28 Nkd2 as target for treating renal fibrosis
CN202180087798.6A CN116783210A (zh) 2020-10-30 2021-10-28 Nkd2作为治疗肾纤维化的靶点
JP2023526269A JP2023549706A (ja) 2020-10-30 2021-10-28 腎線維症の治療標的としてのＮｋｄ２
PCT/EP2021/080068 WO2022090434A1 (de) 2020-10-30 2021-10-28 Nkd2 als target zur behandlung von nierenfibrose
KR1020237017649A KR20230098243A (ko) 2020-10-30 2021-10-28 신장 섬유증 치료를 위한 표적으로서의 nkd2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102020128677.5A DE102020128677A1 (de) 2020-10-30 2020-10-30 Ein neues Target zur Behandlung der Nierenfibrose

Publications (1)

Publication Number Publication Date
DE102020128677A1 true DE102020128677A1 (de) 2022-05-05

Family

ID=78528918

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102020128677.5A Pending DE102020128677A1 (de) 2020-10-30 2020-10-30 Ein neues Target zur Behandlung der Nierenfibrose

Country Status (8)

Country Link
US (1) US20240391985A1 (https=)
EP (1) EP4237078A1 (https=)
JP (1) JP2023549706A (https=)
KR (1) KR20230098243A (https=)
CN (1) CN116783210A (https=)
CA (1) CA3195914A1 (https=)
DE (1) DE102020128677A1 (https=)
WO (1) WO2022090434A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO2000049034A1 (en) 1999-02-17 2000-08-24 The Board Of Trustees Of The Leland Stanford Junior University Naked cuticle genes and their uses
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
WO2009007861A1 (en) 2007-07-07 2009-01-15 Chamed Srl Implantable rf defibrillator

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US9970935B2 (en) * 2014-02-06 2018-05-15 The Brigham And Women's Hospital, Inc. Uses of GLI1 in detecting tissue fibrosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO2000049034A1 (en) 1999-02-17 2000-08-24 The Board Of Trustees Of The Leland Stanford Junior University Naked cuticle genes and their uses
WO2009007861A1 (en) 2007-07-07 2009-01-15 Chamed Srl Implantable rf defibrillator

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRGIC A. IVICIA u.a.: Translational Profiles of Medullary Myofibroblasts during Kidney Fibrosis, 2014, Vol. 25 (9), S. 1979-1990

Also Published As

Publication number Publication date
EP4237078A1 (de) 2023-09-06
US20240391985A1 (en) 2024-11-28
JP2023549706A (ja) 2023-11-29
CA3195914A1 (en) 2022-05-05
CN116783210A (zh) 2023-09-19
WO2022090434A1 (de) 2022-05-05
KR20230098243A (ko) 2023-07-03

Similar Documents

Publication Publication Date Title
Chen et al. Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer
Tsukui et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis
Wang et al. EGFR-Aurka signaling rescues polarity and regeneration defects in dystrophin-deficient muscle stem cells by increasing asymmetric divisions
Heymann et al. Polypropylene mesh implantation for hernia repair causes myeloid cell–driven persistent inflammation
Rock et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition
Rinon et al. p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes
Barinov et al. Essential role of immobilized chemokine CXCL12 in the regulation of the humoral immune response
Yang et al. Overexpression of inhibitor of DNA-binding 2 attenuates pulmonary fibrosis through regulation of c-Abl and Twist
Chen et al. Cross-species single-cell analysis uncovers the immunopathological mechanisms associated with IgA nephropathy progression
Duerr et al. A constitutively expressed fluorescent ubiquitination-based cell-cycle indicator (FUCCI) in axolotls for studying tissue regeneration
JP2025090705A (ja) 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
CN119074926A (zh) 一种靶向fap的car-t细胞在制备治疗心肌炎慢性期心脏纤维化的药物中的应用
Zhou et al. Single‐Cell Analysis Reveals Fibroblast‐Derived Migrasomes as CXCL12 Carriers Promoting Skin Wound Repair
WO2017053952A1 (en) Targeting fibroblast invasion for pulmonary fibrosis
DE102020128677A1 (de) Ein neues Target zur Behandlung der Nierenfibrose
EP4630817A1 (de) Adamts12 als zielmolekül zur behandlung chronischer niereninsuffizienz und nierenfibrose
WO2004005540A2 (de) Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen
Zhang et al. Monocyte-derived macrophage recruitment mediated by TRPV1 is required for eardrum wound healing
US20240165195A1 (en) Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
Li et al. Skeletal Muscle Stem Cells Modulate Niche Function in Duchenne Muscular Dystrophy through YY1-CCL5 Axis
KR102698088B1 (ko) Ctcf매개 전사체 응축 촉진용 조성물
DE102024112149A1 (de) ADAMTS12 und HMCN1 als Zielmoleküle zur Behandlung chronischer Niereninsuffizienz und Nierenfibrose
Melica Glomerular crescents derive from hyperplasia of single progenitors and drug enhancing their differentiation into podocytes attenuates crescentic glomerulonephritis
Seufert Elucidating the role of Musashi RNA-binding proteins in tubular epithelial cells and acute kidney injury
Kastlmeier Engineering a 3D human lung model system to study the disease crosstalk within the alveolar epithelium

Legal Events

Date Code Title Description
R163 Identified publications notified